Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Top 5 Stock Picks of Farallon Capital

In this article, we discuss the top 5 stock picks of Farallon Capital. If you want to read our detailed analysis of these stocks, go directly to Farallon Capital: A Global and Diversified Hedge Fund and its Top Stock Picks.

5. SDCL EDGE Acquisition Corporation (NYSE:SEDA)

Farallon Capital Equity Stake: $18.08 Million
Number of Hedge Fund Holders: N/A

SDCL EDGE Acquisition Corporation (NYSE:SEDA) founded in 2021 and headquartered in New York City, aims to merge with or acquire businesses in the built environment and transport sectors. It primarily focuses on designing, constructing, and operating physical infrastructure.

The hedge fund owned 1.73 million shares of SDCL EDGE Acquisition Corporation (NYSE:SEDA). The hedge fund’s stake in SEDA was worth $18.08 million. This investment made up 0.1% of the hedge fund’s portfolio.

Follow Sdcl Edge Acquisition Corp (NYSE:SEDA)

[/company-follow-email]

4. Savara, Inc. (NASDAQ:SVRA)

Farallon Capital Equity Stake: $34.85 Million
Number of Hedge Fund Holders: 10

Headquartered in Austin, Texas, Savara, Inc. (NASDAQ:SVRA) develops inhaled therapies for rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor for treating autoimmune pulmonary alveolar proteinosis.

Savara, Inc. (NASDAQ:SVRA) is already up by more than 100% for the year, affirming its status as one of Farallon’s top stock picks in the healthcare sector. The hedge fund owns stakes worth $34.85 million, accounting for 0.19% of the portfolio.

During the second quarter, ten hedge funds had positions in Savara, Inc. (NASDAQ:SVRA), according to Insider Monkey’s database. 

Follow Savara Inc (NASDAQ:SVRA)

[/company-follow-email]

3. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA

Farallon Capital Equity Stake: $40.13 Million
Number of Hedge Fund Holders: 14

Another top stock that Farallon Capital invests in is Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). This company is focused on finding and creating small molecule drugs that can treat viral infections and liver diseases. Enanta Pharmaceuticals, Inc. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) researches and develops disease targets that include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.

Farallon Capital has been buying and selling shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) since 2017. As of the end of the second quarter, it held stakes worth $40 million, accounting for 0.22% of the portfolio.

As of Q2 2022, 14 of the 910 hedge funds tracked by Insider Monkey owned shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), valued at 119.41 million, Thomas Steyer’s Farallon Capital was its second-largest shareholder after Armistice Capital, with ownership of 1.88 million shares.

Follow Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

[/company-follow-email]

2. Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Farallon Capital Equity Stake: $124.61 Million
Number of Hedge Fund Holders: 34 

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company that develops novel peptide-based drugs for haematology and blood disorders and inflammatory and immunomodulatory diseases.

Farallon Capital participated in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)’s $100 million financing in 2021. Protagonist is up by about 27%, affirming its status as one of Farallon Capital’s top stock picks in the healthcare sector. The hedge fund owns $124.61 million worth of stakes in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), having bought stakes in the company in 2017 for the first time.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) saw a significant increase in hedge fund interest in the second quarter, according to Insider Monkey’s database. The number of bullish hedge funds rose from 23 in the previous quarter to 34 in the second quarter.

Follow Protagonist Therapeutics Inc (NASDAQ:PTGX)

[/company-follow-email]

1. Aramark (NYSE:ARMK)

Farallon Capital Equity Stake: $468.68 Million
Number of Hedge Fund Holders: 25

Aramark (NYSE:ARMK) is another Farallon Capital top stock pick in the industrials sector, specializing in providing food, facilities and uniform services to education, healthcare, business, and sports clients. Aramark (NYSE:ARMK) offers food-related managed services, including dining, catering, food service management and convenience-oriented retail services.

Aramark (NYSE:ARMK) became an investment target for Farallon Capital in 2020, when the COVID-19 pandemic was at its peak. The hedge fund had a position of 10.89 million shares in Aramark (NYSE:ARMK), which was valued at $468.68 million. However, the hedge fund’s investment in ARMK had decreased by 4% in value since the previous quarter, representing 2.61% of its portfolio allocation.

Aramark (NYSE:ARMK) attracted 25 hedge funds out of the 910 that Insider Monkey tracks in the June quarter of 2023. 

Follow Aramark (NYSE:ARMK)

[/company-follow-email]

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out our articles on Billionaire Ray Dalio’s 15 Best Stock Picks and Billionaire David Tepper Doesn’t Like Most Stocks But He Likes These 12.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.